# AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

> **NCT06646055** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 110 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** AK112, Cadonilimab, nab-paclitaxel, gemcitabine
- **DRUG:** AK112, Cadonilimab, nab-paclitaxel, gemcitabine
- **DRUG:** AK112, Cadonilimab, nab-paclitaxel, gemcitabine
- **DRUG:** AK112, nab-paclitaxel, gemcitabine
- **DRUG:** nab-paclitaxel, gemcitabine

## Key facts

- **NCT ID:** NCT06646055
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-21
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646055, "AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06646055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*